|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-1-22
|
|
pubmed:abstractText |
The poor outcomes in patients with acute kidney injury (AKI) and end-stage renal disease (ESRD) on chronic dialysis are due to immune dysregulation associated with these disorders. Evolving evidence suggests that the kidney, and specifically renal epithelial cells, plays an important role in the immunological response of leukocytes under disease states.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1421-9735
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
183-90
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20093825-Acute Kidney Injury,
pubmed-meshheading:20093825-Anticoagulants,
pubmed-meshheading:20093825-Antigen-Presenting Cells,
pubmed-meshheading:20093825-Atherosclerosis,
pubmed-meshheading:20093825-Cardiovascular Diseases,
pubmed-meshheading:20093825-Citric Acid,
pubmed-meshheading:20093825-Cytokines,
pubmed-meshheading:20093825-Double-Blind Method,
pubmed-meshheading:20093825-Equipment Design,
pubmed-meshheading:20093825-Female,
pubmed-meshheading:20093825-Hemofiltration,
pubmed-meshheading:20093825-Heparin,
pubmed-meshheading:20093825-Humans,
pubmed-meshheading:20093825-Kidney Failure, Chronic,
pubmed-meshheading:20093825-Kidney Tubules, Proximal,
pubmed-meshheading:20093825-Leukocyte Reduction Procedures,
pubmed-meshheading:20093825-Leukocytes,
pubmed-meshheading:20093825-Lymphocyte Activation,
pubmed-meshheading:20093825-Male,
pubmed-meshheading:20093825-Middle Aged,
pubmed-meshheading:20093825-Multiple Organ Failure,
pubmed-meshheading:20093825-Prospective Studies,
pubmed-meshheading:20093825-Systemic Inflammatory Response Syndrome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Mich., USA. dhumes@med.umich.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
